Ambarish Pandey, M.D.: Internal ...

Dr. Ambarish Pandey, MD

Claim this profile

University of Texas Southwestern Medical Center

Studies Heart Failure
Studies Type 2 Diabetes
14 reported clinical trials
21 drugs studied

Affiliated Hospitals

Image of trial facility.

University Of Texas Southwestern Medical Center

Image of trial facility.

UT Southwestern Medical Center

Clinical Trials Ambarish Pandey, MD is currently running

Image of trial facility.

LoDoCo

for Heart Failure

The purpose of this research study is to determine the effectiveness of low dose colchicine (LoDoCo) on measures of exercise capacity, physical function, frailty, and quality of life, among patients with heart failure with chronic stable preserved ejection fraction (HFpEF) and systemic inflammation. The use of LoDoCo in this study is considered investigational as it has not been approved by the Food and Drug Administration (FDA) for the treatment of exercise capacity in patients with HFpEF. Participants will undergo a 1-day screening that includes a blood draw and physical examination. If deemed eligible for the study, participants will undergo a baseline visit within 2 weeks of screening visit that includes physical examination, exercise testing, echocardiography and completion of quality-of-life surveys. Participants will also be randomized at this visit (randomly assigned to a group) to receive either LoDoCo or placebo (inactive substance) for 3 months. Participants will be called back at 3 months for repeat physical examination, blood draws, echocardiography, exercise testing and completion of quality-of-life surveys. Each visit will take about 3 hours. Total study duration is about 3 months.

Recruiting

0 awards

Phase 2

9 criteria

Image of trial facility.

Polypill

for Cardiomyopathy Prevention in Type 2 Diabetes

This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily. The study duration is 6 months, and participants will be randomized to either polypill therapy or simultaneous prescription of the individual drugs. The primary outcome is change in peak VO2 and adherence to usual care. The investigators hypothesize that the use of a polypill is feasible and improves medication adherence and peak VO2 as compared to those receiving usual care.

Recruiting

1 award

Phase 1 & 2

1 criteria

More about Ambarish Pandey, MD

Clinical Trial Related

3 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Ambarish Pandey, MD has experience with

  • Placebo
  • Polypill
  • Ultromics EchoGo HFpEF Algorithm
  • Control Treatment
  • Financial Support
  • Low Dose Colchicine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Ambarish Pandey, MD specialize in?

Is Ambarish Pandey, MD currently recruiting for clinical trials?

Are there any treatments that Ambarish Pandey, MD has studied deeply?

What is the best way to schedule an appointment with Ambarish Pandey, MD?

What is the office address of Ambarish Pandey, MD?

Is there any support for travel costs?